VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced the voting results from its annual general and special meeting (the “Meeting”) held on September 23, 2016.
A total of 26,558,396 shares were represented at the Meeting, being 73.50% of the Company’s issued and outstanding common shares. The shareholders voted on and approved all matters brought before the Meeting, including the appointment of EisnerAmper LLP, Chartered Accountants as auditors of the Company and to authorize the directors to fix their remuneration, the election of the directors of the Company, and an advisory resolution to approve the Company’s approach to executive compensation.
Detailed results of the vote for the election of directors are provided below:
|Votes For||Votes Withheld|
|Election of Directors|
|Michel De Wilde||18,116,389||99.98%||3,056||0.02%|
|Steven D. Rubin||18,017,032||99.43%||102,413||0.57%|
The Company is also pleased to announce that the Chief Financial Officer of VBI Vaccines Inc. (Delaware) prior to the merger (the “Merger”) of the Company (then SciVac Therapeutics Inc.) and VBI Vaccines Inc. (Delaware), Egidio Nascimento, has been named Chief Financial Officer of the Company. The Company would like to thank James J. Martin for his role as Chief Financial Officer of the Company during the Company’s transition period post-Merger.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, “forward-looking statements”) that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company’s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.
VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company’s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
(617) 830-3031 x124
VBI Investor Contact
Director, Corporate Development and Investor Relations
(617) 830-3031 x128